Literature DB >> 10722523

Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates.

K E Warren1, C M McCully, T J Walsh, F M Balis.   

Abstract

Antifungal prophylaxis in cancer patients who are undergoing chemotherapy is associated with prolonged neutropenia. We measured the effect of fluconazole on doxorubicin pharmacokinetics in nonhuman primates to determine if neutropenia is related to a pharmacokinetic interaction that delays the clearance of the chemotherapeutic agent. Fluconazole pretreatment had no effect on doxorubicin pharmacokinetics.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10722523      PMCID： PMC89824          DOI： 10.1128/AAC.44.4.1100-1101.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias.

Authors:  J Palmblad; B Lönnqvist; B Carlsson; G Grimfors; M Järnmark; R Lerner; P Ljungman; C Nyström-Rosander; B Petrini; G Oberg
Journal:  J Intern Med       Date:  1992-04       Impact factor: 8.989

Review 2.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid.

Authors:  C L McCully; F M Balis; J Bacher; J Phillips; D G Poplack
Journal:  Lab Anim Sci       Date:  1990-09

4.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

5.  The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.

Authors:  N L Harris; D E Brenner; L B Anthony; J C Collins; S Halter; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 6.  Prevention of invasive fungal infections in patients with neoplastic disease.

Authors:  T J Walsh; J W Lee
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

7.  Severe candidal infections in neutropenic patients.

Authors:  J N Swerdloff; S G Filler; J E Edwards
Journal:  Clin Infect Dis       Date:  1993-11       Impact factor: 9.079

8.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

Review 9.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

10.  Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias.

Authors:  A Schaffner; M Schaffner
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.